ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 23 Issue : 1
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Heart transplantation [Anatol J Cardiol]
Anatol J Cardiol. 2008; 8(Suppl. 2): 131-147

Heart transplantation

Ozan Erbasan, Cemal Kemaloğlu, Ömer Bayezid
Department of Cardiovascular Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkey

End-stage heart failure is still associated with a decrease in both quality and prognosis of life and one- year survival of these patients is below 50%. Heart transplantation remains the final therapeutic option for the treatment of irreversible end-stage heart failure in all age groups with adequate success rates. Survival of patients who underwent heart transplantation has improved incrementally in recent years, with 86% survival in the first year and over 50% survival at 10 years. Approximately 50% of patients live for more than 10 years after heart transplantation and 25% of patients live for more than 18 years. Improvement of the quality of life is an other benefit, while the patients were in NYHA class III-IV preoperatively, nearly all of them have an improved functional status with NYHA class I-II after transplantation. However, discrepancy between the number of candidates and number of available donors is still the major problem for the applicability of heart transplantation.

Keywords: heart transplantation, immunosuppression, rejection, cardiac allograft vasculopathy, endomyocardial biopsy


Ozan Erbasan, Cemal Kemaloğlu, Ömer Bayezid. Heart transplantation. Anatol J Cardiol. 2008; 8(Suppl. 2): 131-147

Corresponding Author: Ozan Erbasan, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology